David is an expert in measuring and valuing health outcomes to inform economic evaluation. His research is both methodological and applied, and typically involves patient–reported outcome measures (PROMs) and/or preference elicitation. The latter includes the generation of value sets to enable the estimation of quality–adjusted life years (QALYs), examining patients’ preferences for different types of treatment, and exploring societal preferences for different health policies. David is a member of the EuroQol Group Association and was recently appointed to serve on the Valuation Working Group. He has published widely in peer–reviewed journals and is a regular contributor at international health economics conferences.

David’s recent methodological research has involved exploring issues related to the valuation of EQ–5D–Y (the child–friendly version of EQ–5D); the measurement of carer quality of life and its consideration in economic evaluation; the prioritisation of treatments for severe diseases in health technology assessment; and the measurement of the benefits of treatments for subfertility. He also has ongoing applied research into the preferences of people with acute leukaemia and their carers, and is a co–investigator on the EQ–5D–Y valuation study for the United Kingdom.